Dr. Leyland-Jones on Breast Cancer Risk Assessment Tools
Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.
Dr. Leyland-Jones Discusses the Phase III HERA Trial
Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.
Dr. Leyland-Jones Discusses Genome Sequencing
Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
2 Clarke Drive Cranbury, NJ 08512